Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vicky Makker

Showing results (111-120 of 140) with videos related to

Pageof 14
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 22, 2023
Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's ChoiceDomenica Lorusso, Nicoletta Colombo, Antonio Casado Herraez, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 26, 2026
Clinical behavior of FIGO stage I endometrioid endometrial adenocarcinoma diagnosed as high grade on pre-operative biopsy and low grade on hysterectomy specimenTiffany Y Sia, Sally Kraiem, Kendal Rosalik, et al.
Gynecologic Oncology|May 28, 2023
Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinomaEric Rios-Doria, Amir Momeni-Boroujeni, Claire F Friedman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2024
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial CancerAngela K Green, Qin Zhou, Alexia Iasonos, et al.
Gynecologic Oncology Reports|April 18, 2022
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinomaElizabeth H Stover, Niya Xiong, Andrea P Myers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2023
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775Vicky Makker, Nicoletta Colombo, Antonio Casado Herráez, et al.
Scientific Reports|October 21, 2020
Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancersHarini Veeraraghavan, Claire F Friedman, Deborah F DeLair, et al.
Gynecologic Oncology|November 24, 2019
Clinical outcomes of patients with POLE mutated endometrioid endometrial cancerMarina Stasenko, Irina Tunnage, Charles W Ashley, et al.
JCO Precision Oncology|January 29, 2026
Age-Related Germline Landscape of Endometrial Cancer: Focus on Early-Onset CasesJudy J Wang, Juliet Milani, Sarah Kane, et al.
Gynecologic Oncology|February 24, 2021
Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancerArnaud Da Cruz Paula, Deborah F DeLair, Lorenzo Ferrando, et al.
Pageof 14

Showing results (111-120 of 140) with videos related to

Sort By:
Pageof 14
European Journal of Cancer (Oxford, England : 1990)|April 22, 2023
Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's ChoiceDomenica Lorusso, Nicoletta Colombo, Antonio Casado Herraez, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 26, 2026
Clinical behavior of FIGO stage I endometrioid endometrial adenocarcinoma diagnosed as high grade on pre-operative biopsy and low grade on hysterectomy specimenTiffany Y Sia, Sally Kraiem, Kendal Rosalik, et al.
Gynecologic Oncology|May 28, 2023
Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinomaEric Rios-Doria, Amir Momeni-Boroujeni, Claire F Friedman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2024
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial CancerAngela K Green, Qin Zhou, Alexia Iasonos, et al.
Gynecologic Oncology Reports|April 18, 2022
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinomaElizabeth H Stover, Niya Xiong, Andrea P Myers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2023
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775Vicky Makker, Nicoletta Colombo, Antonio Casado Herráez, et al.
Scientific Reports|October 21, 2020
Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancersHarini Veeraraghavan, Claire F Friedman, Deborah F DeLair, et al.
Gynecologic Oncology|November 24, 2019
Clinical outcomes of patients with POLE mutated endometrioid endometrial cancerMarina Stasenko, Irina Tunnage, Charles W Ashley, et al.
JCO Precision Oncology|January 29, 2026
Age-Related Germline Landscape of Endometrial Cancer: Focus on Early-Onset CasesJudy J Wang, Juliet Milani, Sarah Kane, et al.
Gynecologic Oncology|February 24, 2021
Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancerArnaud Da Cruz Paula, Deborah F DeLair, Lorenzo Ferrando, et al.
Pageof 14